524 related articles for article (PubMed ID: 17229553)
1. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
2. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
5. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
7. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
10. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates.
Hoehn R; Groll AH; Schaefer V; Bauer K; Schloesser RL
Int J Antimicrob Agents; 2006 Mar; 27(3):256-8. PubMed ID: 16480855
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates.
Cilli F; Pullukcu H; Aydemir S; Sipahi OR; Tasbakan M; Turhan A; Ulusoy S
Int J Antimicrob Agents; 2008 Mar; 31(3):297-8. PubMed ID: 18180144
[No Abstract] [Full Text] [Related]
12. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Raad II; Hanna HA; Hachem RY; Dvorak T; Arbuckle RB; Chaiban G; Rice LB
Antimicrob Agents Chemother; 2004 Sep; 48(9):3583-5. PubMed ID: 15328133
[TBL] [Abstract][Full Text] [Related]
13. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.
Pankey G; Ashcraft D; Patel N
Antimicrob Agents Chemother; 2005 Dec; 49(12):5166-8. PubMed ID: 16304195
[TBL] [Abstract][Full Text] [Related]
14. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.
Werner G; Klare I; Spencker FB; Witte W
J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253
[TBL] [Abstract][Full Text] [Related]
15. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin-resistant Enterococcus faecium meningitis in adults: case series and review of the literature.
Knoll BM; Hellmann M; Kotton CN
Scand J Infect Dis; 2013 Feb; 45(2):131-9. PubMed ID: 22992165
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
18. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
19. New antimicrobial agents for the treatment of Gram-positive bacterial infections.
Aksoy DY; Unal S
Clin Microbiol Infect; 2008 May; 14(5):411-20. PubMed ID: 18261129
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]